0.00Open0.04Pre Close0 Volume133 Open Interest8.00Strike Price0.00Turnover3235.15%IV13.48%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-7DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type-0.0967Delta0.2025Gamma230.00Leverage Ratio-23.1410Theta0.0000Rho-22.24Eff Leverage0.0000Vega
Aurinia Pharmaceuticals Stock Discussion
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced the acceptance of six abstracts at the American Society of Nephrology (ASN) Kidney Week 2024. The data reinforces the clinical importance of LUPKYNIS® (voclosporin) for treating adults with active lupus nephritis (LN). Key highlights include:
...
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
No comment yet